Regulations Causing Innovation Failure, Impact Pfizer - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulations Causing Innovation Failure, Impact Pfizer

ePT--the Electronic Newsletter of Pharmaceutical Technology

According to the UK’s Economic and Social Research Council (ESRC), the closure of Pfizer’s UK research and development (R&D) facility, announced last week, is part of a long-term decline in drug development that is affecting all major UK pharmaceutical multinationals. The ESRC blames the decline on “failure of innovative drive in the industry, failure of the UK to support basic research, failure of venture capital to invest in early-stage research, or failure of the Health Service to provide smart procurement.”

In particular, the stunted innovation has been attributed to the “lengthy and expensive regulatory system,” according to an ESRC press statement. Although regulation impacts all products developed by any industry sector, it is significantly felt in the pharma industry, where it affects overall company strategies, which companies succeed and fail, and, ultimately, the entire structure and dynamism of the sector as a whole.

According to research by the ESRC’s Innogen Center, the pharmaceutical industry is approaching a “tipping point” in the not-too-distant future in which innovation will no longer be sustainable. However, “radical reform” of regulatory systems could help to better ensure a productive and profitable pharma sector—both globally and in the UK.

“We do not need less regulation, but smarter regulation that can deliver expected standards of safety and efficacy, and that is flexible enough to respond to new scientific discoveries and do so more efficiently than our current systems within a shorter timeframe,” Professor Joyce Tait, director of the ESRC's Innogen Center, said in the statement.

ESRC believes that radical regulatory reform for the life-sciences industries should be a priority in discussions regarding the industry’s future. “Reform could provide the lever to profitably unleash the creativity that has been so effectively generated from public funding of basic science, leading to something closer to the innovative performance that we have seen in information and communication technologies over the past 20 years,” said the ESRC in the press statement.

See a related blog post on PharmTech Talk, titled, Pfizer Site Closure “Shocking Wake-Up Call” for UK


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here